Merck Q2: $MRCK Keytruda Hits $8.4B But Earnings Face Pressure

$MRK just dropped a solid Q2 report, and the numbers look good on the surface: $16.6 billion in revenue, up 5% year-over-year, topping expectations. Keytruda sales hit $8.4 billion, continuing its run as the most dominant oncology drug in the world. Winrevair, Merck's pulmonary hypertension bet, posted 75% growth. On paper, this is a company humming.

So why is the Seeking Alpha quant model sitting at Hold? The short answer: the Prometheus acquisition. Merck bought Prometheus Biosciences for roughly $10.8 billion in 2023 to get its hands on a promising inflammatory bowel disease drug. The math isn't fully working yet, and near-term EPS pressure from that deal is weighing on the forward picture even as Keytruda keeps printing money.

Here's the bull case: Keytruda is still growing at a healthy clip with multiple new indications being explored, Winrevair looks like a genuine second act, and Merck has a track record of turning acquisitions into long-term drivers. The pipeline is not empty. For income-focused investors, the dividend consistency grades out at A+, and that's not nothing in a market where a lot of pharma names are cutting or freezing payouts.

The bear case is a bit thornier. Keytruda faces patent expiration pressure in the late 2020s, and right now it represents roughly half the company's revenue. That's a concentration risk that makes analysts nervous, especially with biosimilar competition looming. The Prometheus bet needs to prove itself quickly, or this starts looking like an expensive science experiment.

Where does retail sentiment land? Social chatter tracked by BullApe shows cautious positioning ahead of the print, with most discussion centering on the Keytruda cliff rather than celebrating the Q2 beat. YouTube commentary from Seeking Alpha's earnings coverage flagged the Hold rating prominently, which tends to dampen retail enthusiasm even when headline numbers look fine. Nobody's chasing this one into a record.

Merck is the kind of stock that earns a place in a diversified portfolio with minimal drama, right up until it doesn't. Watch the Prometheus pipeline readouts in the next two quarters, because that's the real earnings story hiding under the Keytruda highlight reel.